Please assess the completion status of the following clinical trial:

Trial Title: Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Preterm infants between 24 and 33 6/7 weeks gestation~* must be less than or equal to 1 week of age~Exclusion Criteria:~* infants who are considered by the medical team to be non-viable~* infants with multiple or severe congenital anomalies such as gastroschisis, congenital chylothorax or other illnesses that do not allow a feeding tube to be placed or utilized at 7 days of age.~* term infants: who are born to mothers with diabetes or are small for gestational age (SGA-less than the 10th% for adjusted gestational age~* All families consented for this study will need to be able to read and write English~* Mother must be 18 years of age or older~* Taking Omegaven

- Gender: ALL
- Minimum Age: 24 Weeks
- Maximum Age: 33 Weeks
- Healthy Volunteers: t

Study Arms:
- DHA oil (Type: ACTIVE_COMPARATOR): DHA oil administered 50 mg/d (0.18ml)as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
- (MCT) control oil (Type: PLACEBO_COMPARATOR): MCT oil administered 0.18ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.

Based on this trial design, predict the completion outcome and termination type (if applicable).